Andembry access in Pakistan: the DRAP named-patient pathway
How patients in the Islamic Republic of Pakistan legally obtain Andembry (garadacimab-gxii) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Andembry in Pakistan
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Patients in Pakistan access Andembry (garadacimab-gxii) for routine prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and adolescents 12 years of age and older through the DRAP named-patient pathway, a Drug Regulatory Authority of Pakistan-administered mechanism that allows a Pakistani-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and how to get a written quote.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Andembry reaches patients in Pakistan
Andembry (garadacimab-gxii, a fully human monoclonal antibody from CSL Behring that selectively inhibits activated factor XII upstream of the kallikrein-kinin pathway, FDA-approved 16 June 2025 for routine prophylaxis of hereditary angioedema attacks in adults and adolescents 12 years and older, administered subcutaneously once monthly) is not currently visible on the DRAP registered-product verification portal at dra.gov.pk/e-services/online-data-verification as of 2026-06-01. Patients access Andembry under the Special Permission for Import of Therapeutic Goods for Personal Use (the patient-named No Objection Certificate or NOC), administered by the Import and Export Section of the DRAP Quality Assurance and Laboratory Testing Division under the Drugs Act 1976 read with the Drugs (Import and Export) Rules 1976 and DRAP Guidance Document QALT/GL/IP/004 at dra.gov.pk Guidance. The application is filed online via the DRAP Special Permissions portal at dra.gov.pk Special Permissions. DRAP does not publish a fixed processing-time SLA; patient-org reporting indicates several working days when documentation is complete. For Andembry specifically, the clinical justification must reference confirmed Type I or Type II HAE diagnosis (C1-inhibitor antigen and function plus C4 testing), prior attack frequency and severity for prophylaxis indication, the patient's previous prophylaxis exposure if any (lanadelumab, berotralstat, C1-INH concentrate), age 12 years or older per the FDA Andembry label, and the VANGUARD phase 3 trial evidence base for FXIIa inhibition (NCT04739059). The prescribing allergist-immunologist or internal medicine specialist with HAE expertise must be registered with the Pakistan Medical and Dental Council. The NOC is single-consignment, scaled by the DRAP guidance convention to roughly three months of supply per filing, and chronic monthly subcutaneous prophylaxis requires re-filing each shipment cycle. A parallel hospital-led pathway under the Special Permission for Institutional Import framework allows institutional importers to file on the prescribing physician's behalf.
Where Andembry is dispensed in Pakistan
Andembry is a subcutaneous monoclonal antibody supplied as a prefilled syringe or prefilled pen administered once monthly. The dispensing site must maintain 2 to 8 degrees Celsius refrigerated storage with continuous temperature logging, an allergy or immunology service that can run baseline diagnostic workup (C1-INH antigen, C1-INH function, C4 complement, plus C1q where the diagnosis is suspected acquired rather than hereditary), patient self-administration training, and an HAE attack-management on-call plan that pairs prophylaxis with on-demand therapy (icatibant, ecallantide, or C1-INH concentrate).
What Andembry costs in Pakistan
Medicine price: quote on request. You get a written quote for your case before you commit. The State Bank of Pakistan outward remittance allowance for medical purposes at sbp.org.pk is a practical sequencing constraint for chronic indefinite prophylaxis. CSL Behring US patient services do not extend to Pakistani residents.
Funding and access barriers for Andembry in Pakistan
Public-sector funding of named-patient HAE prophylaxis biologic imports in Pakistan is largely case-by-case. The Sehat Sahulat Programme at pmhealthprogramme.gov.pk covers inpatient hospitalisation and selected chronic-disease therapies for enrolled families; the per-family annual ceiling does not stretch to a year of an imported US biologic and the programme is built around in-network empaneled hospital treatment rather than imported drug procurement. Khyber Pakhtunkhwa's Sehat Card Plus has the broadest provincial specialty cover. Pakistan Bait-ul-Mal at pbm.gov.pk offers case-by-case grants for high-cost foreign-sourced treatment. Private insurers do not publish an unlicensed-drug formulary, and chronic monoclonal-antibody HAE prophylaxis coverage is uncommon given the indefinite duration and annual budget impact. Pakistan's out-of-pocket share of health expenditure consistently sits above 50 percent per World Bank data at data.worldbank.org; for HAE prophylaxis cases the dominant pattern is self-pay supplemented by family fundraising, Bait-ul-Mal grants, charity-hospital channels, and overseas-relative remittances from the GCC, UK, and North America. DRAP import permit handling for monoclonal antibody prefilled syringes is procedurally straightforward but cold-chain compliance documentation at the dispensing pharmacy is the practical binding step.
Recent regulatory and access news for Andembry
DRAP published the consolidated Guidance Document for Applicants on Import and Export Permissions of Therapeutic Goods (QALT/GL/IP/004) covering personal-use, institutional, and donation imports, the current operative reference for any Andembry NOC application; full notice at dra.gov.pk regulatory updates. The Federal Cabinet of Pakistan approved an exemption for the import of unregistered drugs in defined public-interest cases under Section 23 of the Drugs Act 1976, broadening the institutional-import lane for rare drugs not commercially available in Pakistan, reported at Express Tribune. On the manufacturer side, the EU Commission granted marketing authorisation for Andembry in February 2025 and the UK MHRA approved Andembry in March 2025, providing reference-authority approvals frequently cited in DRAP justifications for personal-use NOC files. No drug-specific DRAP bulletin for Andembry over the last 12 months has been observed as of 2026-06-01.
Where Reserve Meds fits in Andembry cases
Reserve Meds is a US-based digital health company. We do not replace your treating physician, we do not replace DRAP, and we do not replace your dispensing pharmacy. For Andembry specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Pakistan, and give you one point of contact through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Andembry case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DRAP application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the case coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Andembry is a once-monthly subcutaneous injection from a pre-filled syringe; allergist/immunology follow-up captures attack frequency, breakthrough rescue use, and antibody-development monitoring.
Next step
If your Pakistani physician has prescribed Andembry and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.